First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2017 Dec 17

PMID 29246961

Citations 17

Authors

Tarek Alsaied

Shankar Baskar

Munes Fares

Fares Alahdab

Richard J Czosek

Mohammad Hassan Murad

Larry J Prokop

Allison A Divanovic

Affiliations

Soon will be listed here.

Abstract

Background: There is no consensus on the most effective and best tolerated first-line antiarrhythmic treatment for fetal tachyarrhythmia. The purpose of this systematic review and meta-analysis was to compare the efficacy, safety, and fetal-maternal tolerance of first-line monotherapies for fetal supraventricular tachycardia and atrial flutter.

Methods And Results: A comprehensive search of several databases was conducted through January 2017. Only studies that made a direct comparison between first-line treatments of fetal tachyarrhythmia were included. Outcomes of interest were termination of fetal tachyarrhythmia, fetal demise, and maternal complications. Ten studies met inclusion criteria, with 537 patients. Overall, 291 patients were treated with digoxin, 137 with flecainide, 102 with sotalol, and 7 with amiodarone. Digoxin achieved a lower rate of supraventricular tachycardia termination compared with flecainide (odds ratio [OR]: 0.773; 95% confidence interval [CI], 0.605-0.987; I=34%). In fetuses with hydrops fetalis, digoxin had lower rates of tachycardia termination compared with flecainide (OR: 0.412; 95% CI, 0.268-0.632; I=0%). There was no significant difference in the incidence of maternal side effects between digoxin and flecainide groups (OR: 1.134; 95% CI, 0.129-9.935; I=80.79%). The incidence of maternal side effects was higher in patients treated with digoxin compared with sotalol (OR: 3.148; 95% CI, 1.468-6.751; I=0%). There was no difference in fetal demise between flecainide and digoxin (OR: 0.767; 95% CI, 0.140-4.197; I=44%).

Conclusions: Flecainide may be more effective treatment than digoxin as a first-line treatment for fetal supraventricular tachycardia.

Citing Articles

Advances and challenges of prenatal interventions for fetal tachyarrhythmias.

Tang J, Huang P, Deng X, Zhao L, Zhai Y, Wang T Front Pediatr. 2025; 12:1509158.

PMID: 39741767 PMC: 11685122. DOI: 10.3389/fped.2024.1509158.

Diagnosis and Management of Fetal Arrhythmias in the Current Era.

Killen S, Strasburger J J Cardiovasc Dev Dis. 2024; 11(6).

PMID: 38921663 PMC: 11204159. DOI: 10.3390/jcdd11060163.

Refractory supraventricular fetal tachycardia as a cause of non-immune hydrops: management conundrum.

Agarwal A, Saha S, Kaur A, Naganur S BMJ Case Rep. 2023; 16(12).

PMID: 38154874 PMC: 10759031. DOI: 10.1136/bcr-2023-255808.

Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS.

Starodubtseva N, Kindysheva S, Potapova A, Kukaev E, Khodzhaeva Z, Bockeria E Int J Mol Sci. 2023; 24(3).

PMID: 36768172 PMC: 9916042. DOI: 10.3390/ijms24031848.

Impact of Abnormal Potassium on Arrhythmia Risk During Pediatric Digoxin Therapy.

Mlambo V, Algaze C, Mak K, Collins 2nd R Pediatr Cardiol. 2022; 45(4):901-908.

PMID: 36403164 DOI: 10.1007/s00246-022-03051-3.

References

SHENKER L . Fetal cardiac arrhythmias. Obstet Gynecol Surv. 1979; 34(8):561-72. DOI: 10.1097/00006254-197908000-00001. View

Simpson J, Sharland G . Fetal tachycardias: management and outcome of 127 consecutive cases. Heart. 1999; 79(6):576-81. PMC: 1728723. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Krapp M, Baschat A, Gembruch U, Geipel A, Germer U . Flecainide in the intrauterine treatment of fetal supraventricular tachycardia. Ultrasound Obstet Gynecol. 2002; 19(2):158-64. DOI: 10.1046/j.0960-7692.2001.00562.x. View

Krapp M, Kohl T, Simpson J, Sharland G, Katalinic A, Gembruch U . Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart. 2003; 89(8):913-7. PMC: 1767787. DOI: 10.1136/heart.89.8.913. View

Khositseth A, Ramin K, OLeary P, Porter C . Role of amiodarone in the treatment of fetal supraventricular tachyarrhythmias and hydrops fetalis. Pediatr Cardiol. 2003; 24(5):454-6. DOI: 10.1007/s00246-002-0337-7. View

Ekman-Joelsson B, Mellander M, Lagnefeldt L, Sonesson S . Foetal tachyarrhythmia treatment remains challenging even if the vast majority of cases have a favourable outcome. Acta Paediatr. 2015; 104(11):1090-7. DOI: 10.1111/apa.13111. View

Echt D, Liebson P, Mitchell L, Peters R, BARKER A, Arensberg D . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324(12):781-8. DOI: 10.1056/NEJM199103213241201. View

OSullivan J, Gardiner H, Wren C . Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants?. J Am Coll Cardiol. 1995; 26(4):991-4. DOI: 10.1016/0735-1097(95)00291-9. View

10.

Donofrio M, Moon-Grady A, Hornberger L, Copel J, Sklansky M, Abuhamad A . Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014; 129(21):2183-242. DOI: 10.1161/01.cir.0000437597.44550.5d. View

11.

Sridharan S, Sullivan I, Tomek V, Wolfenden J, Skovranek J, Yates R . Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols. Heart Rhythm. 2016; 13(9):1913-9. DOI: 10.1016/j.hrthm.2016.03.023. View

12.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

13.

Stewart P, Witsenburg M, den Hollander N, Wladimiroff J, Hess J . The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. Prenat Diagn. 1995; 15(13):1297-302. DOI: 10.1002/pd.1970151309. View

14.

Pezard P, Boussion F, Sentilhes L, Lepinard C, Couvreur M, Victor J . Fetal tachycardia: a role for amiodarone as first- or second-line therapy?. Arch Cardiovasc Dis. 2008; 101(10):619-27. DOI: 10.1016/j.acvd.2008.08.012. View

15.

Jouannic J, Le Bidois J, Fermont L, Villain E, Mahieu-Caputo D, Dumez Y . Prenatal ultrasound may predict fetal response to therapy in non-hydropic fetuses with supraventricular tachycardia. Fetal Diagn Ther. 2002; 17(2):120-3. DOI: 10.1159/000048021. View

16.

Strizek B, Berg C, Gottschalk I, Herberg U, Geipel A, Gembruch U . High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia. Heart Rhythm. 2016; 13(6):1283-8. DOI: 10.1016/j.hrthm.2016.01.029. View

17.

Kerenyi T, Gleicher N, Meller J, Brown E, STEINFELD L, Chitkara U . Transplancental cardioversion of intrauterine supraventricular tachycardia with digitalis. Lancet. 1980; 2(8191):393-4. DOI: 10.1016/s0140-6736(80)90441-9. View

18.

Jaeggi E, Ohman A . Fetal and Neonatal Arrhythmias. Clin Perinatol. 2016; 43(1):99-112. DOI: 10.1016/j.clp.2015.11.007. View

19.

Jaeggi E, Carvalho J, De Groot E, Api O, Clur S, Rammeloo L . Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011; 124(16):1747-54. DOI: 10.1161/CIRCULATIONAHA.111.026120. View

20.

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View